Neurodegenerative diseases (NDs) have a serious impact on global health with no effective treatments available to date. Vaccination has been proposed as a therapeutic approach for NDs, and clinical evaluations of some candidates for Alzheimer's disease and multiple sclerosis are ongoing. Moreover, monoclonal antibodies for passive immunotherapy are under evaluation for Alzheimer's, synucleinopathies, and multiple sclerosis. Areas covered: With the consolidation of plant-based systems for the production and oral delivery of biopharmaceuticals, interesting perspectives arise in the fight against NDs. Based on analysis of the current biomedical literature, the role of plant-made biopharmaceuticals and the outlook on how this technology is leading to new therapeutic candidates and potential developments for NDs are presented in this review. Expert commentary: Substantial innovations in the following years are expected as a consequence of applying molecular pharming in the fight against NDs.
Keywords: Alzheimer’s disease; Biopharmaceuticals; Parkinson’s disease; multiple sclerosis; oral delivery; transgenic plant.